# Effect of continuous positive airway pressure therapy on stroke risk and rehabilitation in population with obstructive sleep apnea: A PRISMAcompliant systematic review and meta-analysis

# Chenlu Zhang, Yalan Fang

Department of Neurology, First Hospital, Shanxi Medical University, Taiyuan, Shanxi Province, China

## Abstract

Background: Previous studies reported inconsistent results regarding the effect of continuous positive airway pressure (CPAP) therapy on stroke risk and rehabilitation in population with obstructive sleep apnea (OSA). The present study aimed to make a meta-analysis to explore the effect of CPAP therapy on stroke risk and rehabilitation in OSA. Methods: Articles published in English before March 2021 in the databases as follows: PubMed, Medline, Web of Science, EMBASE and Google Scholar. For the effect of CPAP therapy on risk of stroke. We computed the results of relative risk (RR) or hazard ratio (HR) and 95% confidence intervals (CIs) regarding the effect of CPAP therapy on risk of stroke. For the effect of CPAP therapy on stroke rehabilitation, the standardized mean differences (SMD) in change rates of National Institute of Health stroke scale (NIHSS) or Canadian Neurological Scale (CNS) scores with a 95% CI was obtained with STATA 12.0 software to estimate the treatment effect. Results: The study indicated no significant effect of CPAP therapy on stroke risk in patients with OSA  $(RR/HR = 0.67, 95\% CI 0.39 \text{ to } 1.16, I^2 = 84.1\%, p < 0.001)$ . However, the study showed a better neurological outcome in OSA patients with stroke treated with CPAP plus usual care, compared to those treated with usual-care (SMD = 0.45, 95% CI 0.03 to 0.87, I<sup>2</sup> = 73.9%, p = 0.001). Conclusion: The present study showed that CPAP therapy did not prevent stroke in patients with OSA. However, the study showed a neurofunctional improvement with CPAP therapy in OSA patients

Keywords: Continuous positive airway pressure, meta-analysis, obstructive sleep apnea, stroke.

#### INTRODUCTION

with stroke.

As known, obstructive sleep apnea (OSA) is related to cardiovascular diseases (CVD) such as coronary artery disease, arrhythmia, hypertension, heart failure and stroke.1 At present, continuous positive airway pressure (CPAP) is the most effective therapy for OSA.<sup>2</sup> CPAP therapy could improve the breathing pattern during sleep, resulting in improvement of health status and depressive symptoms.<sup>3</sup> In addition, meta-analyses showed that treatment with CPAP was associated with a significantly lower risk of major adverse cardiovascular event (MACE). Regarding the effect of CPAP therapy on stroke risk in OSA, Molnar et al. reported that CPAP treated OSApositive patients showed decreased risk of stroke, compared to untreated OSA-positive patients.<sup>4</sup> However, other studies showed no significant

effect of CPAP therapy on stroke risk in OSA.<sup>5,6</sup> The present study aimed to make a meta-analysis to explore the effect of CPAP therapy on stroke risk in OSA.

In addition, the estimated prevalence of OSA is 38% to 70% in stroke patients.<sup>7</sup> Some studies showed that CPAP treatment improves neurologic outcomes of stroke patients with OSA.<sup>8,9</sup> However, some studies showed no significant effect of CPAP treatment on rehabilitation in OSA.<sup>10,11</sup> The present study aimed to make a meta-analysis to explore the effect of CPAP therapy on stroke rehabilitation in OSA.

#### **METHODS**

This study was based on the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guideline.<sup>12</sup>

Address correspondence to: Yalan Fang, Department of Neurology, First Hospital, Shanxi Medical University, No. 85, Jiefang South Road, Yingze District, Taiyuan, 030001, Shanxi Province, China. Tel: +86-0351-4867029, E-mail: yalan1923fang@126.com

Date of Submission: 5 April 2021; Date of Acceptance 7 April 2021

#### Search strategy and selection criteria

Articles published in English before March 2021 in the databases as follows: PubMed, Medline, Web of Science, EMBASE and Google Scholar. These search terms: ('continuous positive airway pressure' OR 'CPAP') AND ('stroke') were used. After eliminating duplicates, 645 studies were included. For the effect of CPAP therapy on risk of stroke in population with OSA, we included cohort studies and randomized controlled trials (RCTs), reporting relative risk (RR) or hazard ratio (HR) and 95% CI associated with CPAP therapy and risk of stroke. For the effect of CPAP therapy on stroke rehabilitation in population with OSA, we included studies with randomized clinical trials (RCTs) design and investigating the influence of CPAP therapy on scores of National Institute of Health stroke scale (NIHSS) or Canadian Neurological Scale (CNS). We excluded metaanalyses, reviews and case reports.

## Data extraction and analysis

STATA 12.0 software was applied to compute results extracted from included studies. The following data were extracted from included studies: Author, publication year, study type, subgroups, numbers of participants, information of included participants (age and gender), body mass index (BMI), apnea-hypopnea index (AHI), CPAP use time, follow-up years, events for analysis, adjustment factor and results. We used Q test and I<sup>2</sup> to evaluate heterogeneities between studies. When the heterogeneity was high (p value for Q test  $\leq$  0.05), we used random effects models as pooling methods; with low heterogeneity (p value for Q test > 0.05), fixed effects models were used as pooling methods. For the effect of CPAP therapy on risk of stroke, we computed the results (RRs or HRs and 95% confidence intervals (CIs) regarding the effect of CPAP therapy on risk of stroke). For the effect of CPAP therapy on stroke rehabilitation, the standardized mean differences (SMD) in change rates of NIHSS or CNS scores with a 95% CI was obtained with STATA 12.0 software to estimate the treatment effect. In addition, we applied subgroup analyses and meta-regression analyses to investigate source of the heterogeneity. We used sensitivity analysis to assess the stabilization of the study. Finally, we used Begg's test, Egger's test and funnel plot to assess publication bias.

# RESULTS

#### Study selection and characteristics

Figure 1 illustrated the selection procedures and results. Characteristics of the finally included 18 studies were showed in Supplementary Tables 1 and 2. For the effect of CPAP therapy on risk of stroke, the study included 4 cohort studies<sup>4,13-15</sup> (including 3,006 OSA patients with CPAP treatment and 25,857 OSA patients without treatment) and 7 RCTs<sup>5,6,16-20</sup> (including 3,006 OSA patients with CPAP plus usual care treatment and 23,158 OSA patients with usual-care). In addition, the study included 7 RCTs.<sup>8-11,21-23</sup> including 190 OSA patients with CPAP plus usual care treatment and 191 OSA patients with usual-care to evaluate the effect of CPAP therapy on stroke rehabilitation in population with OSA.

# Meta-analysis results

The study indicated no significant effect of CPAP therapy on stroke risk in patients with OSA (RR/ HR = 0.67, 95% CI 0.39 to 1.16,  $I^2 = 84.1\%$ , p < 0.001, Figure 2). In addition, subgroup study showed no significant effect of CPAP therapy on stroke risk in patients with OSA in both RCTs and cohort studies (RCTs: HR = 0.91, 95% CI 0.68 to 1.22,  $I^2 = 0.0\%$ , p = 0.532; cohort studies: RR = 0.60, 95% CI 0.28 to 1.30,  $I^2 = 87.0\%$ , p < 0.001; Figure 3). Subgroup study showed that therapy with CPAP did not prevent stroke in patients with OSA in both Caucasian and Asian populations (Caucasian: RR/HR = 0.67, 95% CI 0.34 to 1.34,  $I^2 = 87.4\%$ , p < 0.001; Asian: RR/HR = 0.73, 95% CI 0.45 to 1.19,  $I^2 = 0.0\%$ , p = 0.402; Figure 4). Meta-regression analysis showed that gender, age, AHI and follow-up time were not responsible for heterogeneity across studies (gender: p = 0.992; age: p = 0.698; AHI: p = 0.959; follow-up time: p = 0.673). Sensitivity analysis showed no changes in direction of effect when any one study was excluded in the meta-analysis (Supplementary Figure 1. A). No significant risk of publication bias was showed for the meta-analysis by Begg's test, Egger's test and funnel plot (Begg's test: p = 0.213; Egger's test: p = 0.125; Supplementary Table 2. A).

The study showed a better neurological outcome in OSA patients with stroke treated with CPAP plus usual care, compared to those treated with usual-care (SMD = 0.45, 95% CI 0.03 to 0.87,  $I^2 = 73.9\%$ , p = 0.001; Figure 5). Sensitivity analysis showed no changes in direction of effect when any one study was excluded in the



Figure 1. Flow of information through the different phases of a meta-analysis. Abbreviations: CI, confidence interval; CNS, Canadian Neurological Scale; CPAP, continuous positive airway pressure; HR, hazard ratio; NIHSS, National Institute of Health stroke scale; OSA, obstructive sleep apnea; RR, relative risk.

meta-analysis (Supplementary Figure 1. B). No significant risk of publication bias was showed for the meta-analysis by Begg's test, Egger's test and funnel plot (Begg's test: p = 0.881; Egger's test: p = 0.109; Supplementary Table 2. B).

#### DISCUSSION

The present study showed no significant effect of CPAP therapy on stroke risk in patients with OSA. However, the study showed a better neurological outcome in OSA patients with stroke treated with CPAP plus usual care, compared to those treated with usual-care.

Regarding the effect of CPAP therapy on stroke risk in OSA, the present study showed that CPAP therapy did not prevent stroke in patients with OSA. The present study included 4 cohort studies and 7 RCTs. A previous meta-analysis with cohort studies showed that treatment with CPAP was associated with a lower incidence of stroke (RR: 0.27, 95%CI: 0.14-0.5).24 But this result could not be reproduced in the RCTs and the studies using administrative data.<sup>24</sup> Molnar et al. reported that CPAP treated OSA patients showed decreased risk of stroke, compared to untreated OSA patients in a cohort study.<sup>4</sup> RCTs were with shorter follow-up period than cohort studies and showed limited power to evaluate the effect of CPAP on stroke separately.17 However, metaregression analysis in the present study showed no effect of follow-up period on the heterogeneity between included studies. Additionally, in some studies, OSA patients with CPAP therapy might show more severe OSA, compared to untreated group.<sup>25</sup> Thus, more prospective studies were essential to explore the effect of CPAP therapy on stroke risk in OSA.

Additionally, this study showed a neurofunctional improvement with CPAP therapy in OSA patients with stroke. This result correspond to a recent meta-analysis including

Study		%
ID	RR/HR (95% CI)	Weight
McEvoy et al, 2016	0.97 (0.69, 1.35)	14.06
Peker et al, 2016	0.50 (0.13, 1.95)	7.82
Campos-Rodriguez et al, 2014	0.91 (0.43, 1.95)	11.59
Sánchez-de-la-Torre et al, 2019	1.59 (0.52, 4.85)	9.21
Molnar et al, 2015 -	0.27 (0.22, 0.32)	14.59
Chang et al, 2019	0.68 (0.38, 1.23)	12.69
Barbé et al, 2012	1.54 (0.18, 18.56)	4.09
Wu et al, 2015	1.03 (0.41, 2.54)	10.54
Huang et al, 2015 -	0.15 (0.01, 2.74)	3.05
McMillan et al, 2014	0.49 (0.05, 5.37)	4.03
Parra et al, 2014 (Spain)	0.45 (0.13, 1.63)	8.32
Overall (I-squared = 84.1%, p = 0.000)	0.67 (0.39, 1.16)	100.00
i	1	
.01 1	100	

Figure 2. Forest plots regarding effect of CPAP therapy on stroke risk in patients with OSA. Abbreviations: CI, confidence interval; CPAP, continuous positive airway pressure; HR, hazard ratio; OSA, obstructive sleep apnea; RR, relative risk.



Figure 3. Subgroup studies regarding effect of CPAP therapy on stroke risk in patients with OSA in RCTs and cohort studies. Abbreviations: CI, confidence interval; CPAP, continuous positive airway pressure; HR, hazard ratio; OSA, obstructive sleep apnea; RR, relative risk.



Figure 4. Subgroup studies regarding effect of CPAP therapy on stroke risk in patients with OSA in Caucasian and Asian populations. Abbreviations: CI, confidence interval; CPAP, continuous positive airway pressure; HR, hazard ratio; OSA, obstructive sleep apnea; RR, relative risk.



Figure 5. Forest plots regarding neurological outcome in OSA patients with stroke treated with CPAP plus usual care, compared to those treated with usual-care. Abbreviations: CI, confidence interval; CPAP, continuous positive airway pressure; OSA, obstructive sleep apnea; SMD, standardized mean difference.

6 RCTs, which showed that neurofunctional scales (NIHSS and CNS) showed an overall neurofunctional improvement with CPAP (SMD 0.5406, 95% CI 0.0263-1.0548) but with a considerable heterogeneity ( $I^2 = 78.9\%$ , p = 0.0394) across the studies.<sup>26</sup> OSA after stroke might have an influence on oxygenation and perfusion of the penumbra, which might adversely affect stroke outcome.<sup>26,27</sup> The early use of CPAP might prolong survival of the penumbra, resulting in clinical and imaging improvement in stroke patients. Additionally, the use of continuous CPAP therapy could independently result in improving cognitive deficit and depression, leading to better participation of stroke patient in the rehabilitation program, which result in a more positive impact on recovery after stroke.23

There are some limitations in the present study. Firstly, regarding the effect of CPAP therapy on stroke risk in OSA, the amount of included studies was limited to explore the sources of heterogeneities. Secondly, regarding the effect of CPAP therapy on stroke rehabilitation in OSA, the number of included studies was small.

In conclusion, the present study showed that CPAP therapy did not prevent stroke in patients with OSA. However, the study showed a neurofunctional improvement with CPAP therapy in OSA patients with stroke.

# REFERENCES

- 1. Somers VK, White DP, Amin R, *et al.* Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation scientific statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. *Circulation* 2008;118(10):1080-111.
- Birkbak J, Clark AJ, Rod N H. The effect of sleep disordered breathing on the outcome of stroke and transient ischemic attack: a systematic review. *J Clin Sleep Med* 2014, 10(1): 103-8.
- Giles TL, Lasserson TJ, Smith BJ, et al. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006, 1): Cd001106.
- Molnar MZ, Mucsi I, Novak M, et al. Association of incident obstructive sleep apnoea with outcomes in a large cohort of US veterans. *Thorax* 2015, 70(9): 888-95.
- Mcevoy RD, Antic NA, Heeley E, *et al.* CPAP for prevention of cardiovascular events in obstructive sleep apnea. *N Engl J Med* 2016, 375(10): 919-31.
- 6. Peker Y, Glantz H, Eulenburg C, Wegscheider K, Herlitz J, Thunstrom E. Effect of positive airway pressure on cardiovascular outcomes in coronary

artery disease patients with nonsleepy obstructive sleep apnea. The RICCADSA Randomized Controlled Trial. *Am J Respir Crit Care Med* 2016;194(5):613-20.

- Johnson KG, Johnson DC. Frequency of sleep apnea in stroke and TIA patients: a meta-analysis. J Clin Sleep Med 2010, 6(2): 131-7.
- Bravata DM, Concato J, Fried T, *et al.* Continuous positive airway pressure: evaluation of a novel therapy for patients with acute ischemic stroke. *Sleep* 2011; 34(9): 1271-7.
- Ryan CM, Bayley M, Green R, *et al.* Influence of continuous positive airway pressure on outcomes of rehabilitation in stroke patients with obstructive sleep apnea. *Stroke* 2011, 42(4): 1062-7.
- Hsu CY, Vennelle M, Li HY, *et al.* Sleep-disordered breathing after stroke: a randomised controlled trial of continuous positive airway pressure. *J Neurol Neurosurg Psychiatry* 2006, 77(10): 1143-9.
- Aaronson JA, Hofman WF, Van Bennekom CA, et al. Effects of continuous positive airway pressure on cognitive and functional outcome of stroke patients with obstructive sleep apnea: A randomized controlled trial. J Clin Sleep Med 2016, 12(4): 533-41.
- Moher D, Librati A, Tetzlaff J, Altman DG, PRISMA Group. *et al.* Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6(7):e1000097.
- Campos-Rodriguez F, Martinez-Garcia MA, Reyes-Nuñez N, Caballero-Martinez I, Catalan-Serra P, Almeida-Gonzalez CV. Role of sleep apnea and continuous positive airway pressure therapy in the incidence of stroke or coronary heart disease in women. *Am J Resp Crit Care Med* 2014; 189(12): 1544-50.
- 14. Chang ET, Chen W, Wang LY, Chen SF, Hsu CY, Shen YC. Continuous positive pressure therapy usage and incident stroke in patients with obstructive sleep apnea: A nationwide population-based cohort study. *Clin Resp J* 2020; 14(9):822-8.
- 15. Wu X, Lv SH, Yu XH, Yao LY, Mokhlesi B, Wei YX. Treatment of OSA reduces the risk of repeat revascularization after percutaneous coronary intervention. *Chest* 2015, 147(3): 708-18.
- 16. Sanchez-de-la-Torre M, Sanchez-de-la-Torre A, Bertran S, *et al.* Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial. *Lancet Resp Med* 2020; 8(4): 359-67.
- Barbe F, Duran-Cantolla J, Sanchez-de-la-Ttorre M, et al. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. JAMA 2012, 307(20): 2161-8.
- Huang ZW, Liu ZH, Luo Q, *et al.* Long-term effects of continuous positive airway pressure on blood pressure and prognosis in hypertensive patients with coronary heart disease and obstructive sleep apnea: a randomized controlled trial. Am *J Hypertens* 2015; 28(3): 300-6.

- McMillan A, Bratton DJ, Faria R, *et al.* Continuous positive airway pressure in older people with obstructive sleep apnoea syndrome (PREDICT): a 12-month, multicentre, randomised trial. *Lancet Resp Med* 2014; 2(10): 804-12.
- Parra O, Sanchez-Armengol Á, Capote F, et al. Efficacy of continuous positive airway pressure treatment on 5-year survival in patients with ischaemic stroke and obstructive sleep apnea: a randomized controlled trial. J Sleep Res 2015; 24(1): 47-53.
- Parra O, Sanchez-Armengol A, Bonnin M, *et al.* Early treatment of obstructive apnoea and stroke outcome: a randomised controlled trial. *Eur Resp J* 2011, 37(5): 1128-36.
- 22. Minnerup J, Ritter MA, Wersching H, *et al.* Continuous positive airway pressure ventilation for acute ischemic stroke: a randomized feasibility study. *Stroke* 2012; 43(4): 1137-9.
- 23. Kim HW, Im SB, Park JI, Kim YW, Sohn MK, Lee SJ. Improvement of cognitive function after continuous positive airway pressure treatment for subacute stroke patients with obstructive sleep apnea: A randomized controlled trial. *Brain Sci* 2019; 9(10):252.
- 24. Kim Y, Koo YS, Lee HY, *et al.* Can continuous positive airway pressure reduce the risk of stroke in obstructive sleep apnea patients? A systematic review and meta-analysis. *PLoS One* 2016; 11(1): e0146317.
- 25. Lamberts M, Nielsen OW, Lip GY, et al. Cardiovascular risk in patients with sleep apnoea with or without continuous positive airway pressure therapy: follow-up of 4.5 million Danish adults. J Int Med 2014, 276(6): 659-66.
- Brill AK, Horvath T, Seiler A, *et al.* CPAP as treatment of sleep apnea after stroke: A meta-analysis of randomized trials. *Neurology* 2018; 90(14): e1222-e30.
- 27. Duss SB, Seiler A, Schmidt MH, *et al.* The role of sleep in recovery following ischemic stroke: A review of human and animal data. *Neurobiol Sleep Circadian Rhythms* 2017; 2:94-105.

Supplementary Table 1	. Charac	teristics of 11	studies regard	ing effe	ct of CPAP th	nerapy on str	oke risk in p	atients w	ith OSA	
References (country)	Study type	Group	Sample Size (male %)	Mean Age	Apnea- hypopnea index/h, mean (SD)	Follow- up(years), median	Events for analysis	Cases	Adjustment factor	Results
McEvoy <i>et al.</i> <sup>1</sup> 2016, (Asia, Australia,	RCT	CPAP	1346 (81.1%)	61.3	29.0 (15.9)	3.7	Incident stroke	67	NR	HR: 0.97 (0.69–1.35)
Europe, North and South America)		Usual-Care	1341 (80.7%)	61.2	29.6 (16.4)			68		
Peker <i>et al.</i> <sup>2</sup> , 2016 (Sweden)	RCT	CPAP	122 (82.0%)	65.5	28.3 (12.7)	4.75	Incident stroke	б	NR	HR: 0.50 (0.13-1.95)
		Usual-Care	122 (86.1%)	66.5	29.3 (14.0)			9		~
Campos-Rodriguez	Cohort	AHI <10	258 (0)	52	4	6.8	Incident	10	age, BMI,	RR:
<i>et at.</i> ;, 2014 (Spam)	study	AHI ≥10 & Untreated	268 (0)	49	24		suroke	38	nypertension, type 2 diabetes mellitus, atrial	Arti ≥10 &Untreated: 2.76 (1.35-5.62)
		AHI ≥10 & CPAP	441 (0)	58	42.8			23	fibrillation	ÁHI ≥10 & CPAP: 0.91 (0.43-1.95)
Sánchez-de- la-Torre <i>et al.</i> <sup>4</sup> ,	RCT	CPAP	629 (84%)	59.9	36.4 (18.6)	3.35	Incident stroke	8	NR	HR: 1.59 (0.52-4.85)
2019 (Spain)		Usual-Care	626 (85%)	60.7	35.5 (18.3)			5		
Molnar <i>et al.</i> <sup>5</sup> , 2015 (USA)	Cohort study	OSA(-)	3056272 (93%)	61	NR	7.74	Incident stroke	50333	age, gender, race/ethnicity,	HR: OSA(+)&Untreated:
		OSA(+)& Untreated	21764 (96%)	59				1601	baseline eGFR, comorbidities	3.48 (3.28-3.64) OSA(+)&CPAP:
		OSA(+)& CPAP	1478 (96%)	57				122	at baselme, measures of quality of care, income, marital	3.50 (2.92-4.19)
									status, BMI	

E1

Supplementary <b>T</b>	able 1. Ch	aracteristics o	f 11 studies re <sub>i</sub>	garding	effect of CPA	A therapy on	ı stroke risk i	n patients	s with OSA	
References (country)	Study type	Group	Sample Size (male %)	Mean Age	Apnea- hypopnea index/h, mean (SD)	Follow- up(years), median	Events for analysis	Cases	Adjustment factor	Results
Chang <i>et al.</i> <sup>6</sup> , 2019 (China, Taiwan)	Cohort study	CPAP Usual-Care	959 (83.2%) 959 (82.5%)	51.1 51.3	NR	4.97 5.19	Incident stroke	18 29	gender, age, urbanization degree, baseline comorbidities	RR: 0.68 (0.38-1.23)
Barbé <i>et al</i> .', 2012 (Spain)	RCT	CPAP Usual-Care	357 (87.7%) 366 (83.6%)	52.0 51.8	42 35	4	Incident stroke	<b>6</b> 7	NR	HR: 1.54 (0.18-18.56)
Wu <i>et al.</i> <sup>8</sup> , 2015 (China)	Cohort study	AHI ≥15 &Untreated AHI ≥15 &CPAP	167 (85.6%) 128 (82.8%)	56 54	40.1 46.3	4.8	Incident stroke	14 11	NR	RR: 1.03 (0.41-2.54)
Huang <i>et al.</i> <sup>9</sup> , 2015 (China)	RCT	Control CPAP	37 (86.5%) 36 (77.8%)	62.7 62.0	28.7 (12.4) 28.3 (13.0)	6	Incident stroke	0 3	NR	HR: 0.15 (0.01-2.74)
McMillan <i>et al.</i> <sup>10</sup> , 2014 (UK)	RCT	Control CPAP	138 (79%) 140 (86%)	71.3 70.9	NR	-	Incident stroke	1 2	NR	HR: 0.49 (0.05-5.37)
Parra <i>et al.</i> <sup>11</sup> , 2015 (Spain)	RCT	Control CPAP	69 (69.6%) 57 (71.9%)	65.5 63.7	NR	4.53	Incident stroke	<i>3</i>	NR	HR: 0.45 (0.13-1.63)
Abbreviations: AHI, obstructive sleep apr	apnea-hypo 1ea; RCT, rai	pnea index; BMI ndomized clinica	I, body mass ind I trial; RR, relati	ex; CI, co ve risk.	nfidence interva	al; CPAP, conti	nuous positive :	airway pres	sure; HR, hazard ratio	; NR, not reported; OSA,

Supplementary	Table 2	. Characte	eristics of 8 st	tudies regard	ling the effect	t of CPAP ther	apy on stroke	rehabilitatio	n in OSA	
References (country)	Study type	Group	Sample Size (male %)	Mean Age	BMI, kg/ m <sup>2</sup>	Apnea- hypopnea index/h, mean (SD)	CPAP use, h/night	Follow- up(years), median	Events for analysis	Results
Hsu <i>et al.</i> <sup>12</sup> , 2006 (UK)	RCT	CPAP	15 (73.3%)	74 (73-81)	26.8 (21.9-28.5)	43.1 (35.6-51.8)	1.4	6 mo	NIHSS	NIHSS: Baseline: 5 (4–9) vs. 6
		Usual- Care	15 (60%)	73 (65-77)	25.1 (22.1-33.1)	47.7 (36.5-60.2)	Median 0.16 over 8 wk			(5–8) Outcome: 2 (1–4) vs. 3 (1–6);
Bravata $et al.^{13}, 2011$	RCT	CPAP	31 (67.7%)	70.6 ± 9.4	$26.8 \pm 4.3$	NR	5.10 (4.49– 5.71)	30 d	NIHSS, recurrent	NIHSS: 3.0↓vs. 1.0↓; recurrent
(DSA)		Usual- Care	24 (66.7%)	$71.6 \pm 13.3$	$29.4 \pm 7.2$	NR	×		events	events: 1 (3.2) vs. 3 (12.5)
Parra <i>et al</i> . <sup>14</sup> , 2011 (Spain)	RCT	CPAP	57 (71.9%)	63.7 ± 9.1	$30.2 \pm 4.6$	NR	5.3 (4.99– 5.61)	24 mo	RS Canadian	RS↓: 90.9% vs. 56.3%; Canadian Neurological
		Usual- Care	69 (69.6%)	65.5 ± 9.1	28.8 ± 4	NR			Neurological Scale	Scale: Baseline: 8.3 (1.6) vs. 8.0 (1.9); Outcome: 9.3 (1.3) vs. 9.5 (1.0)
Ryan <i>et al.</i> <sup>15</sup> , 2011 (Canada)	RCT	CPAP	22 (72.7%)	62.8 ± 12.8	28.8 ± 5.3	$38.5 \pm 18.1$	4.96 (4.32-5.60)	4 wk	Canadian Neurological	Canadian Neurological scale: Baseline: 7.3
		Usual- Care	22 (86.4%)	$60.7 \pm 10.3$	27.3 ± 5.8	$33.3 \pm 16.4$			scale	(1.9) vs. 7.7 (1.9) Outcome: 9.6 (1.7) vs. 8.4 (1.5);
Minnerup et al. <sup>16</sup> , 2012	RCT	CPAP	25 (36%)	68.6 (10.0)	27.8 (2.5)	NR	4.2 (3.79–5.61)	8 nights	SSHIN	NIHSS: 2.00 (0.82) ¢ vs. 1.40
		Usual- Care	25 (40%)	63.4 (10.5)	26.7 (3.1)	NR				$(1.53)\downarrow$
Aaronson $et al.^{17}, 2016$	RCT	CPAP	20 (60%)	$61.1 \pm 8.2$	$28.1 \pm 6.4$	$34.2 \pm 14.8$	2.50 (1.59–3.41)	2 mo	SSHIN	NIHSS: 3.50 (3.28) ¢ vs. 2.19
		Usual- Care	16 (62.5%)	56.7 ± 8.8	25.8 ± 4.7	NR				(2.71) ↓
Kim <i>et al.</i> <sup>18</sup> , 2019	RCT	CPAP	20 (65%)	<b>63.3</b> ± <b>13.1</b>	$23.3 \pm 3.7$	$44.4 \pm 16.8$	>4	3-week	SSHIN	NIHSS: $1.5 \pm 1.3$ \vert vs. $1.1 \pm 1.5$
		Usual- Care	20 (80%)	66.9 ± 12.3	$24.4 \pm 3.9$	$34.9 \pm 17.2$				
Abbreviations: BN stroke scale; NR,	AI, body 1 not report	mass index; ed; OSA, of	CI, confidence bstructive sleep	interval; CNS, apnea; RCT, r	Canadian Neu andomized clin	rological Scale; ( ical trial; RS, Rai	CPAP, continuous nkin scale; SD, s	positive airwa tandard deviatio	y pressure; NIHS on.	S, National Institute of Health



Supplementary Figure 1. Sensitivity analysis regarding effect of CPAP therapy on stroke risk (A) and rehabilitation (B) in patients with OSA. Abbreviations: CPAP, continuous positive airway pressure; OSA, obstructive sleep apnea.



Supplementary Figure 2. Funnel plots regarding effect of CPAP therapy on stroke risk (A) and rehabilitation (B) in patients with OSA. Abbreviations: CPAP, continuous positive airway pressure; OSA, obstructive sleep apnea.

#### Supplementary REFERENCES

- Mcevoy RD, Antic NA, Heeley E, *et al.* CPAP for prevention of cardiovascular events in obstructive sleep apnea. *N Engl J Med* 2016, 375(10): 919-31.
- Peker Y, Glantz H, Eulenburg C, Wegscheider K, Herlitz J, Thunstrom E. Effect of positive airway pressure on cardiovascular outcomes in coronary artery disease patients with nonsleepy obstructive sleep apnea. The RICCADSA Randomized Controlled Trial. *Am J Respir Crit Care Med* 2016;194(5):613-20.
- Campos-Rodriguez F, Martinez-Garcia MA, Reyes-Nuñez N, Caballero-Martinez I, Catalan-Serra P, Almeida-Gonzalez CV. Role of sleep apnea and continuous positive airway pressure therapy in the incidence of stroke or coronary heart disease in women. *Am J Resp Crit Care Med* 2014; 189(12): 1544-50.
- 4. Sanchez-de-la-Torre M, Sanchez-de-la-Torre A, Bertran S, *et al.* Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial. *Lancet Resp Med* 2020; 8(4): 359-67.
- Molnar MZ, Mucsi I, Novak M, et al. Association of incident obstructive sleep apnoea with outcomes in a large cohort of US veterans. *Thorax* 2015, 70(9): 888-95
- Chang ET, Chen W, Wang LY, Chen SF, Hsu CY, Shen YC. Continuous positive pressure therapy usage and incident stroke in patients with obstructive sleep apnea: A nationwide population-based cohort study. *Clin Resp J* 2020; 14(9):822-8.
- Barbe F, Duran-Cantolla J, Sanchez-de-la-Ttorre M, et al. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. JAMA 2012, 307(20): 2161-8.
- Wu X, Lv SH, Yu XH, Yao LY, Mokhlesi B, Wei YX. Treatment of OSA reduces the risk of repeat revascularization after percutaneous coronary intervention. *Chest* 2015, 147(3): 708-18.
- Huang ZW, Liu ZH, Luo Q, et al. Long-term effects of continuous positive airway pressure on blood pressure and prognosis in hypertensive patients with coronary heart disease and obstructive sleep apnea: a randomized controlled trial. Am J Hypertens 2015; 28(3): 300-6.
- McMillan A, Bratton DJ, Faria R, et al. Continuous positive airway pressure in older people with obstructive sleep apnoea syndrome (PREDICT): a 12-month, multicentre, randomised trial. Lancet Resp Med 2014; 2(10): 804-12.
- Parra O, Sanchez-Armengol Á, Capote F, et al. Efficacy of continuous positive airway pressure treatment on 5-year survival in patients with ischaemic stroke and obstructive sleep apnea: a randomized controlled trial. J Sleep Res 2015; 24(1): 47-53.
- 12. Hsu CY, Vennelle M, Li HY, *et al*. Sleep-disordered breathing after stroke: a randomised controlled trial

of continuous positive airway pressure. J Neurol Neurosurg Psychiatry 2006, 77(10): 1143-9.

- Bravata DM, Concato J, Fried T, *et al.* Continuous positive airway pressure: evaluation of a novel therapy for patients with acute ischemic stroke. *Sleep* 2011; 34(9): 1271-7.
- Parra O, Sanchez-Armengol A, Bonnin M, et al. Early treatment of obstructive apnoea and stroke outcome: a randomised controlled trial. Eur Resp J 2011, 37(5): 1128-36.
- Ryan CM, Bayley M, Green R, *et al.* Influence of continuous positive airway pressure on outcomes of rehabilitation in stroke patients with obstructive sleep apnea. *Stroke* 2011, 42(4): 1062-7.
- Minnerup J, Ritter MA, Wersching H, et al. Continuous positive airway pressure ventilation for acute ischemic stroke: a randomized feasibility study. *Stroke* 2012; 43(4): 1137-9.
- 17. Aaronson JA, Hofman WF, Van Bennekom CA, et al. Effects of continuous positive airway pressure on cognitive and functional outcome of stroke patients with obstructive sleep apnea: A randomized controlled trial. J Clin Sleep Med 2016, 12(4): 533-41.
- Kim HW, Im SB, Park JI, Kim YW, Sohn MK, Lee SJ. Improvement of cognitive function after continuous positive airway pressure treatment for subacute stroke patients with obstructive sleep apnea: A randomized controlled trial. *Brain Sci* 2019; 9(10):252.